In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
BioMed X EnstitĂĽsĂĽ’nden Dr. Ebru Ercan Herbst: Ĺžizofreni her 100 insanda 1’inde görĂĽlĂĽyor
Independent Türkçe
From the BioMed X Institute, Dr. Ebru Ercan Herbst: Schizophrenia is seen in 1 in every 100 people. Schizophrenia, which starts between the ages of 16 and 30, causes hallucinations, delusions, and disordered thinking.
Leveraging synergies in pre-clinical biomedical R&D – pharmaceutical companies benefit from new innovation models
Word Pharma Today
As the complexity of pharmaceutical research and development increases constantly, its innovation productivity defined as the successful approval and launch of truly novel drugs and therapies, has declined since years.
BioMed X Reaches Milestone in Respiratory Disease Research Collaboration with Boehringer Ingelheim
BioSpace
BioMed X announced today the successful completion of their first joint research project with Boehringer Ingelheim in the fields of chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
15 Most Promising Biotech Startups in Europe – 2019
Startup City
As new technologies emerge, numerous biotech startups are launched across Europe every year. With specialized venture capital firms and technology companies pouring money into the sector, biotech startups now attract record amount of investment.
How researchers are ensuring that their work has an impact
nature
When Melissa Craig realized that biological matter such as algae might slow the speed of powerful underwater landslides by releasing chemicals that help to glue sea-floor mounds together, she failed to share her colleagues’ enthusiasm around the discovery.
BioMed X emerges from Merck KGaA alliance armed with bioinformatics tools
fiercebiotech.com
BioMed X has begun offering bioinformatics services on the back of its alliance with Merck KGaA. The services are underpinned by tools developed during BioMed X’s three-year collaboration with Merck KGaA, during which it advanced computational approaches to the design of highly selective kinase inhibitors.